Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Bipolar Disorder (Jul 2019)

Posted by Matt Breese on Jul 12, 2019

Find me on:

According to our recent payer coverage analysis for bipolar disorder treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for bipolar disorder treatments shows that under the pharmacy benefit, about 43% of the lives under commercial and Medicare formularies are covered with utilization management restrictions.

MMIT-Reality Check-Bipolar Disorder_2Q2019Data snapshot as of Q2 2019

Trends: The market contains multiple strong oral generics. Competition amongest brand name products after failure of oral generics is expected. 

To read the full Reality Check on Bipolar Disorder treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing